Compare
LifeMD, Inc. vs SBC Medical Group Holdings Inc vs Starling Oncology, Inc. vs Hims & Hers Health, Inc.
| Latest fiscal year | LifeMD, Inc. LFMD | SBC Medical Group Holdings Inc SBC | Starling Oncology, Inc. STLN | Hims & Hers Health, Inc. HIMS |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $194.06M | $173.61M | $502.73M | $2.35B |
| Revenue growth (YoY) | +25.3% | -15.5% | +27.8% | +59.0% |
| Gross margin | 85.7% | 73.3% | n/a | 73.8% |
| Operating margin | -4.0% | 38.9% | -7.2% | 4.5% |
| Net margin | 7.4% | 29.4% | -12.1% | 5.5% |
| Net income | $14.35M | $50.99M | -$60.61M | $128.37M |
| EPS (Diluted) | $0.25 | $0.50 | -$0.54 | $0.51 |
| Operating cash flow | $8.28M | $24.67M | -$24.59M | $300.01M |
| Free cash flow | $6.41M | $23.27M | -$27.79M | $57.41M |
| Cash & equivalents | n/a | $163.77M | n/a | $228.62M |
| Total assets | $70.41M | $380.45M | $164.66M | $2.15B |
| Total liabilities | $47.25M | $117.14M | $180.38M | $1.61B |
| Shareholders' equity | $23.16M | $248.28M | -$15.72M | $540.93M |
| Return on year-end equity | 62.0% | 20.5% | n/a | 23.7% |
| Shares outstanding | 46.66M | 102.58M | 98.86M | n/a |
Revenue, most recent five fiscal years
| Fiscal year | LifeMD, Inc. | SBC Medical Group Holdings Inc | Starling Oncology, Inc. | Hims & Hers Health, Inc. |
|---|---|---|---|---|
| Latest | $194.06M Ended 2025-12-31 | $173.61M Ended 2025-12-31 | $502.73M Ended 2025-12-31 | $2.35B Ended 2025-12-31 |
| 1 year earlier | $154.82M Ended 2024-12-31 | $205.42M Ended 2024-12-31 | $393.41M Ended 2024-12-31 | $1.48B Ended 2024-12-31 |
| 2 years earlier | $152.55M Ended 2023-12-31 | $193.54M Ended 2023-12-31 | $324.24M Ended 2023-12-31 | $872.00M Ended 2023-12-31 |
| 3 years earlier | $119.03M Ended 2022-12-31 | n/a | $252.48M Ended 2022-12-31 | $526.92M Ended 2022-12-31 |
| 4 years earlier | $92.88M Ended 2021-12-31 | n/a | $203.00M Ended 2021-12-31 | $271.88M Ended 2021-12-31 |